Full-Time
Manager – Manufacturing Intelligence
Posted on 12/18/2025
Pfizer
10,001+ employees
Biopharmaceutical company develops medicines and vaccines
No salary listed
Remote in India
Remote
 Biology & Biotech (2) |
|---|
| , |
- B. Tech computer science is preferred.
- Expert-level knowledge in Python is a must. Experience in any of the following languages is a plus: R, Matlab, JavaScript.
- Ability to perform data engineering on real world big-data ranging from structured time-series datasets with thousands of features.
- Track record in applying data science and machine learning methodologies to real-world data to generate insight and support decision making.
- Ability to work collaboratively in diverse cross-functional teams on innovative solutions and tools with an open attitude towards fast learning.
- Knowledge of upstream and downstream Biopharmaceutical Manufacturing
- Demonstrated experience of story-telling to technical experts and non-technical stakeholders
- Independent, self-motivated personality with excellent oral and written communication skills
- Technical contribution to high-impact projects that require data analytics, advanced modeling, and optimization expertise.
- Identify high value opportunities for applying Advanced Analytics, Advanced Process Control (APC), Artificial Intelligence (AI), Machine Learning (ML) and Industrial Internet of Things (IIoT), Generative AI and develop and deploy innovative fit-for-purpose solutions in manufacturing environment
- Drive development of mathematical and machine learning models and support GMP implementation of such analytics solutions
- Apply engineering principles, modeling tools, and experimental skills using data-rich lab/pilot/manufacturing equipment to improve process understanding and facilitate real-time process monitoring and control
- Collaborate with cross-functional teams and key stakeholders, effectively communicate progress to management, and drive project progress in a timely manner.
- Expertise in first principles (thermodynamics, reaction modeling, heat transfer, mass transfer principles), hybrid modeling. Ability to develop practical process models for real-time applications is a strong plus.
- Experience deploying Interpretable Machine Learning or Explainable AI and knowledge of Shapley values and plots
- Experience in cloud-based code development and deployment environments such as AWS SageMaker.
- Familiarity with cloud computing based data-warehouses such as Snowflake or Redshift, and relational SQL databases.
- Familiarity with feedback control algorithms, real-time communication protocols, industrial process historians, and industrial automation platforms such as DeltaV and ASPEN.
- Experience in data visualization and real-time GUIs using Streamlit, Plotly, Spotfire, etc.
- Knowledge of Cell Culture, Fermentation and Vaccines Conjugation
Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a range of health needs, including vaccines, oncology, and other specialized therapies. Its products work by using biological mechanisms to prevent or treat diseases—vaccines train the immune system to fight infections, while medicines target cancer and other conditions. Pfizer differentiates itself through its large worldwide footprint, broad portfolio across multiple therapeutic areas, and partnerships (notably with BioNTech) that expanded its reach in vaccines and cutting-edge therapies. The company also engages in public health initiatives, such as efforts to provide vaccines to underserved populations. Pfizer’s broad goal is to improve global health by delivering safe and effective medicines and vaccines through research, development, and wide international distribution.
Company Size
10,001+
Company Stage
IPO
Headquarters
New York City, New York
Founded
1849
Simplify's Take
What believers are saying
- Oncology biosimilars grow 52% operationally in Q1 2026 amid high-margin expansion.
- ELREXFIO Phase 3 data supports earlier multiple myeloma treatment positioning.
- PF-08653944 advances to 10 Phase 3 trials in 2026 with 9.6mg dose.
What critics are saying
- Eliquis patent expires 2028, generics erode $6B annual revenue 70% in 12 months.
- Ibrance generics launch 2027, slash $5B sales 60-80% within 18 months.
- Danuglipron discontinued April 2025 after liver injury in early trials.
What makes Pfizer unique
- VEPPANU secures FDA approval as first PROTAC therapy for ESR1-mutated breast cancer.
- VYNDAMAX patent settlements extend US exclusivity to June 2031.
- PF-08653944 achieves 12.3% placebo-adjusted weight loss monthly in Phase 2b VESPER-3.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Sick Leave
Paid Holidays
Hybrid Work Options
Relocation Assistance
Company News
ANN ARBOR, Mich. & NEW YORK--(BUSINESS WIRE)--ANN ARBOR, Mich
Ten branded pharmaceuticals stocks reported mixed fourth-quarter results, with revenues missing analysts' consensus estimates by 1.7% on average. Share prices have declined 3% on average since the latest earnings results. Pfizer reported revenues of $17.56 billion, down 1.2% year-on-year but exceeding analysts' expectations by 5.5%. The stock has risen 2.8% since reporting and currently trades at $27.40. Eli Lilly delivered the strongest performance amongst peers, reporting revenues of $19.29 billion, up 42.6% year-on-year and beating expectations by 7.4%. Despite the impressive results, shares have fallen 5.2% since reporting to $951.77. The industry faces tailwinds from precision medicine advances and AI adoption, but headwinds include regulatory scrutiny, pricing pressures and patent cliffs for blockbuster drugs.
Pfizer, trading at less than 10 times estimated future earnings, presents significant upside potential despite recent revenue declines. The pharmaceutical company's sales fell from $101 billion in 2022 to under $63 billion last year as COVID-19 product revenues diminished. However, Pfizer has been actively preparing for growth through strategic acquisitions. In 2023, it purchased oncology specialist Seagen for $43 billion, gaining access to promising antibody-drug conjugates for cancer treatment. Last year, it acquired GLP-1 drugmaker Metsera for up to $10 billion to enter the anti-obesity drug market. The company maintains over 100 drug candidates in development. Whilst facing near-term patent cliffs on key drugs, Pfizer's extensive pipeline and low valuation suggest substantial long-term potential for investors willing to accept calculated risk.
Pfizer shares have climbed to $28.30, delivering a 7.1% return over the past six months and outperforming the S&P 500 by 9.4 percentage points. The pharmaceutical company's organic revenue has grown at a solid 10.1% year-on-year average over the last two years, whilst its adjusted operating margin rose 17.8 percentage points to reach 35.1% for the trailing 12 months. However, Pfizer's long-term performance shows slower growth, with revenue expanding at just a 5.6% compound annual growth rate over the past five years, underperforming the broader healthcare sector. The stock currently trades at 9.6× forward price-to-earnings ratio. Founded in 1849, Pfizer develops and manufactures medicines and vaccines for various diseases and conditions globally.
Pfizer shares have risen 25% since Jim Cramer advised investors to "pass" on the stock in April 2025, citing uncertainty over potential tariffs and taxes on pharmaceutical companies. The shares are up 6.7% over the past year and 7.4% year-to-date. A notable gain occurred between 29 September and 1 October, when shares jumped 14% following Pfizer's announcement that it would lower Medicaid drug prices to match those in developing countries as part of the Trump administration's TrumpRx initiative. However, shares fell 3.3% on 3 February after the company reported fourth-quarter results of $17.6 billion in revenue and $0.66 adjusted earnings per share. Pfizer is developing a once-monthly weight loss treatment and currently offers an 8% dividend yield.